Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
Date:11/21/2008

DETROIT, Nov. 21 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Alternext US: CPD) announced today that it will be filing its response to the FDA warning letter on November 24, 2008 as planned. In the warning letter, received on October 31, 2008, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008.

As previously disclosed, the warning letter was issued as a follow up to the last FDA inspection of the Company's manufacturing facility in Detroit, Michigan which was initiated in May 2008. Until the Company's responses to the observations have been clarified and explanations provided to the satisfaction of the FDA, the FDA may in the near term withhold approval of pending new drug applications listing the facility as the manufacturer. The Company's sales of current products continue in the normal course of business.

The Company is committed to working cooperatively and expeditiously with the FDA to resolve the matters indicated in its letter.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
6. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
7. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
8. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
9. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Concorde Career College North Hollywood ... the 2014 Excellence in Community Service Award from ... (ACCSC). , Every year, the Accrediting Commission of ... make outstanding contributions in their local community through ... scope and impact of the community service and ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... September 02, 2014 The performance of ... over the past five years. Industry revenue is estimated ... over the five years through 2014-15, following stabilised growth ... increasing external competition from alternate forms of gambling. Horse ... online gambling platforms have all become increasingly popular over ...
Breaking Medicine News(10 mins):Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:Many nurses unprepared to meet dying patients 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Shengtai Pharmaceutical, Inc. (OTC,Bulletin Board: SGTI) ("Shengtai Pharmaceutical" ... high-quality, pharmaceutical grade,glucose products in China, today reported ... 2007., Second Quarter of Fiscal 2008 ... $25.0 million -- Gross profit rose 91% ...
... treatments for the disease, study suggests , , THURSDAY, Feb. 14 ... cells into mice with hemophilia enables the animals to produce ... hemophilia. , The breakthrough finding may lead the way to ... of the disease, researchers believe. , "We were able to ...
... /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals Corp. (NASDAQ: NCST ; TSX: ... 2007. Net loss narrowed to $4.0 million, or 22,cents ... to a net loss,of $10.5 million, or 58 cents ... year. The lower net loss for 2007 is primarily ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... people,through the U.S. Agency for International Development (USAID), ... Tajikistan after extreme winter weather,and an energy crisis ... This,funding will help provide fuel, heaters, clothing, household ... USAID partners Save the Children,CARE, and Mercy Corps., ...
... 14 Today, Lung Cancer,Alliance announced that for the ... called for a screening program for veterans at high,risk ... USN, (Ret.), chairman of LCA,s Board of,Directors said today, ... these organizations for speaking out about the number one,cancer ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 12Health News:Transplanted Liver Lining Cells May Cure Hemophilia 2Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:Veterans Organizations Call for Lung Cancer Screening 2Health News:Veterans Organizations Call for Lung Cancer Screening 3
(Date:9/2/2014)... Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the Morgan ... at 10:20 a.m. ET. The conference will be held ... New York City . About Abaxis ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... ARLINGTON HEIGHTS, Ill., Sept. 12 Even as,many ... available today,we are stopped by our rear reflection and ... study published in the October issue of Plastic and,Reconstructive ... Plastic Surgeons (ASPS), reveals a new back lift procedure ...
... Ala., Sept. 11 - Southern,Research Institute and ... from a study testing Naltrexone-derived,pyridomorphinan (SoRI-9409) will ... of,the journal Biological Psychiatry. The publication is ... suggests that a new compound that,causes selective ...
Cached Medicine Technology:Say 'Goodbye' to Back Fat Rolls 2Novel Compound Shows Promise for Treatment of Alcoholism 2Novel Compound Shows Promise for Treatment of Alcoholism 3Novel Compound Shows Promise for Treatment of Alcoholism 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: